Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Lite Strategy, Inc. Director's Dealing 2020

Jul 7, 2020

34267_dirs_2020-07-07_bb4f7c30-780f-4981-abb9-18f8bbe14e19.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: MEI Pharma, Inc. (MEIP)
CIK: 0001262104
Period of Report: 2020-07-02

Reporting Person: Reynolds Thomas C (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2020-07-02 Stock Option (Right to Buy) $3.49 A 50000 Acquired 2030-07-02 Common Stock (50000) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $1.57 2025-07-28 Common Stock (20000) 20000 Direct
Stock Option (Right to Buy) $1.36 2026-07-29 Common Stock (40000) 40000 Direct
Stock Option (Right to Buy) $2.83 2027-07-06 Common Stock (40000) 40000 Direct
Stock Option (Right to Buy) $4.28 2028-07-12 Common Stock (40000) 40000 Direct
Stock Option (Right to Buy) $2.52 2029-07-01 Common Stock (40000) 40000 Direct

Footnotes

F1: The options will vest in equal monthly installments over twelve months.

F2: All of such options are presently exercisable.